Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie Acquires 5,000 Shares

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the purchase, the chief financial officer now directly owns 30,000 shares in the company, valued at $175,500. This represents a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Septerna Stock Performance

NASDAQ SEPN traded down $0.09 during trading on Friday, reaching $5.80. The company’s stock had a trading volume of 1,158,707 shares, compared to its average volume of 586,476. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The business’s fifty day moving average is $17.78.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new position in Septerna in the fourth quarter valued at $25,000. New York State Common Retirement Fund acquired a new position in shares of Septerna during the fourth quarter worth about $32,000. Legal & General Group Plc acquired a new position in shares of Septerna during the fourth quarter worth about $42,000. Summit Investment Advisors Inc. acquired a new position in shares of Septerna during the fourth quarter worth about $45,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Septerna during the fourth quarter worth about $52,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Wells Fargo & Company lowered shares of Septerna from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $43.00 to $14.00 in a research note on Tuesday. TD Cowen began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.